- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04359121
COVID-19 and the Developement of Phobic Fears of Disease
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Andreas Baranyi, Prof.
- Phone Number: 0043-316-385-86241
- Email: an.baranyi@medunigraz.at
Study Locations
-
-
Styria
-
Graz, Styria, Austria, 8036
- Recruiting
- Medical University of Graz
-
Contact:
- Andreas Baranyi, Prof. MD
- Phone Number: +4331638586241
- Email: an.baranyi@medunigraz.at
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Person gives written consent
- Persons between 18-90 years of age (men and women)
- No positive COVID infection known at time of first examination
Exclusion Criteria:
- Dementia, Delirium (not able to give consent)
- Not fulfilling the inclusion criteria
- COVID infection known at first examination point
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Physicians
Questionnaires
|
Questionnaires will be used.
|
Medical staff
Questionnaires
|
Questionnaires will be used.
|
General public
Questionnaires
|
Questionnaires will be used.
|
Patients with psychiatric disorders
Questionnaires
|
Questionnaires will be used.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of phobias
Time Frame: 2 years
|
Specific Phobia Questionnaire (SPQ): The SPQ consists of 43 items, each rated using a 5-point Likert scale on two dimensions: (1) level of fear, with scores ranging from 0 (no fear) to 4 (extreme fear) and (2) extent to which the fear interferes with one's daily life, with scores ranging from 0 (no interference) to 4 (extreme interference). The SPQ is scored by combining fear ratings of each Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) specific phobia type. Severity Measure for Specific Phobia-Adult: The total score can range from 0 to 40 with higher scores indicating greater severity of specific phobia. |
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Andreas Baranyi, Prof., Medical University of Graz
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 32-354 ex 19/20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Questionnaires for specific phobia
-
CHU de ReimsCompleted
-
Boston University Charles River CampusNot yet recruitingAnxiety Disorder of Childhood
-
Universitat Jaume IUniversity of ValenciaCompleted
-
Universitat Jaume ICompleted
-
şeyda öztürkCompletedMigraine | Prevalence | Headache Disorders, Primary | Psychosocial Problem | StudentTurkey
-
University Hospital, MontpellierRecruiting
-
Cardiff and Vale University Health BoardUniversity College, London; University Hospital Birmingham NHS Foundation Trust and other collaboratorsCompletedCardiac ArrhythmiaUnited Kingdom
-
AHS Cancer Control AlbertaTom Baker Cancer CentreRecruitingBreast Cancer | Colorectal CancerCanada
-
Maastricht UniversityAristotle University Of Thessaloniki; P1vital Products LTD.; Biotrial; University... and other collaboratorsCompletedDepression | Schizophrenia | Motivation | Anhedonia, Physical | Anhedonia, Social | Negative Symptoms With Primary Psychotic DisorderGermany, Greece, Netherlands, Spain
-
Institute of Psychiatry, LondonCompletedBody Dysmorphic DisorderUnited Kingdom